Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Aligos Therapeutics (ALGS) Return on Capital Employed (2021 - 2025)

Aligos Therapeutics filings provide 5 years of Return on Capital Employed readings, the most recent being 6.44% for Q4 2025.

  • On a quarterly basis, Return on Capital Employed rose 14855.0% to 6.44% in Q4 2025 year-over-year; TTM through Dec 2025 was 6.44%, a 14855.0% increase, with the full-year FY2025 number at 8.63%, up 9146.0% from a year prior.
  • Return on Capital Employed hit 6.44% in Q4 2025 for Aligos Therapeutics, up from 86.52% in the prior quarter.
  • In the past five years, Return on Capital Employed ranged from a high of 6.44% in Q4 2025 to a low of 154.99% in Q4 2024.
  • Median Return on Capital Employed over the past 5 years was 80.97% (2023), compared with a mean of 85.72%.
  • Biggest five-year swings in Return on Capital Employed: crashed -6201bps in 2024 and later skyrocketed 14855bps in 2025.
  • Aligos Therapeutics' Return on Capital Employed stood at 61.03% in 2021, then crashed by -31bps to 79.82% in 2022, then decreased by -16bps to 92.98% in 2023, then crashed by -67bps to 154.99% in 2024, then skyrocketed by 96bps to 6.44% in 2025.
  • The last three reported values for Return on Capital Employed were 6.44% (Q4 2025), 86.52% (Q3 2025), and 64.12% (Q2 2025) per Business Quant data.